If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

Share Price is delayed by 15 minutes
Get Live Data
1,244.00    9.00 (0.73%)
Bid:
1,236.00
Ask:
1,239.00
Spread: 3.00 (0.243%)
Market Cap: £860.84m
CVSG Live PriceLast checked at - London Stock Exchange

Intraday CVS Group Share Chart

Response to CMA Summary Final Decision Report

24 Mar 2026 07:13

RNS Number : 8560X
CVS Group plc
24 March 2026
 

For Immediate Release 24 March 2026

CVS Group plc

("CVS", the "Company" or the "Group")

 

Response to CMA Summary Final Decision Report

 

CVS notes this morning's publication by the Competition and Markets Authority ("CMA") of the summary of its Final Decision Report in the veterinary services market investigation. The CMA is expected to publish its full Final Decision Report later today.

 

CVS welcomes the certainty that this morning's announcement brings after more than two and half years of CMA scrutiny.

 

The CMA's final decision does not introduce any new remedies over and above those announced in its provisional decision. We are pleased to see that the CMA has considered our and the veterinary profession's feedback in amending the proposed fee cap on prescriptions with the cap now increased to £21 inclusive of VAT for the first drug prescribed, with the ability to charge an additional £12.50 for each additional drug prescribed at the same time. Whilst we continue to believe that some of these remedies are not fully justified, we are comfortable with them and believe they are workable. We already comply with many remedies and are well advanced in complying with others, with price lists published on our practice websites in late 2025 and 117 CVS UK companion animal practices already jointly branded.

 

As such, the Board expects the Group to continue to trade in line with market expectations.

 

Whilst the remedies are now certain and will not change, we look forward to discussing the practical implementation of all remedies with the CMA prior to the publication of its Final Order later in 2026 which will bring these remedies into legal effect.

 

Contacts

CVS Group plc via Camarco

Richard Fairman, Chief Executive Officer

Robin Alfonso, Chief Financial Officer

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Camarco (Financial PR)

Ginny Pulbrook cvsg@camarco.co.uk

Tilly Butcher +44 (0)20 3757 4980

Letaba Rimell

 

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPPPURUWUPQUMC
Date   Source Headline
24th Nov 20253:30 pmRNSStandard form for notification of major holdings
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20254:49 pmRNSStandard form for notification of major holdings
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20255:35 pmRNSStandard form for notification of major holdings
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20252:50 pmRNSResult of AGM
18th Nov 20257:00 amRNSAGM Statement and Trading Update
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20254:31 pmRNSPDMR Dealing
17th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSTransaction in Own Shares
13th Nov 20257:00 amRNSTransaction in Own Shares
12th Nov 20257:00 amRNSTransaction in Own Shares
11th Nov 20257:00 amRNSTransaction in Own Shares
10th Nov 20257:00 amRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSTransaction in Own Shares
5th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
3rd Nov 20257:00 amRNSTransaction in Own Shares
31st Oct 20257:00 amRNSTransaction in Own Shares
31st Oct 20257:00 amRNSTotal Voting Rights
30th Oct 20257:00 amRNSTransaction in Own Shares
29th Oct 20257:00 amRNSTransaction in Own Shares
28th Oct 20257:00 amRNSTransaction in Own Shares
27th Oct 20257:00 amRNSTransaction in Own Shares
24th Oct 20257:06 amRNSCommencement of Share Buyback Programme
24th Oct 20257:00 amRNSIntention to move to Main Market & Buyback Scheme
17th Oct 20257:00 amRNSPosting of Annual Report & Notice of AGM
15th Oct 20257:35 amRNSResponse to CMA provisional decision announcement
7th Oct 20257:00 amRNSFinal results for the year ended 30 June 2025
30th Sep 20257:00 amRNSTotal Voting Rights
15th Sep 20254:50 pmRNSPDMR Shareholding Correction
11th Sep 20254:53 pmRNSHolding(s) in Company
9th Sep 20259:46 amRNSHolding(s) in Company
5th Sep 20259:30 amRNSNotification of major holdings
29th Aug 20254:42 pmRNSTotal Voting Rights
5th Aug 202511:19 amRNSStandard form for notification of major holdings
1st Aug 202510:31 amRNSLTIP Awards and PDMR Dealing
31st Jul 20257:00 amRNSTotal Voting Rights
24th Jul 20257:00 amRNSFull year trading update
15th Jul 20255:00 pmRNSStandard form for notification of major holdings
14th Jul 20257:00 amRNSBlock listing Interim Review
11th Jul 20253:48 pmRNSDirector/PDMR Shareholding
2nd Jul 202510:00 amRNSStandard form for notification of major holdings
30th Jun 202510:01 amRNSStandard form for notification of major holdings
30th Jun 20257:00 amRNSTotal Voting Rights
10th Jun 20258:54 amRNSResponse to CMA announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.